These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16626903)

  • 41. The toxicity of sulfamethazine to Daphnia magna and its additivity to other veterinary sulfonamides and trimethoprim.
    De Liguoro M; Fioretto B; Poltronieri C; Gallina G
    Chemosphere; 2009 Jun; 75(11):1519-24. PubMed ID: 19269673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition.
    Buur JL; Baynes RE; Smith GW; Riviere JE
    Res Vet Sci; 2009 Apr; 86(2):293-301. PubMed ID: 18721993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combinations of antimicrobial drugs.
    S Afr Med J; 1969 Feb; 43(5):97. PubMed ID: 5775261
    [No Abstract]   [Full Text] [Related]  

  • 44. BIGL: Biochemically Intuitive Generalized Loewe null model for prediction of the expected combined effect compatible with partial agonism and antagonism.
    Van der Borght K; Tourny A; Bagdziunas R; Thas O; Nazarov M; Turner H; Verbist B; Ceulemans H
    Sci Rep; 2017 Dec; 7(1):17935. PubMed ID: 29263342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug interaction: focusing on response surface models.
    Lee SI
    Korean J Anesthesiol; 2010 May; 58(5):421-34. PubMed ID: 20532049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antagonistic effects of methyl-mercury and PCB153 on PC12 cells after a combined and simultaneous exposure.
    Vettori MV; Goldoni M; Caglieri A; Poli D; Folesani G; Ceccatelli S; Mutti A
    Food Chem Toxicol; 2006 Sep; 44(9):1505-12. PubMed ID: 16757078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.
    Palmer AC; Chidley C; Sorger PK
    Elife; 2019 Nov; 8():. PubMed ID: 31742555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pharmacologic basis for the use of combinations of antimicrobial drugs.
    Jawetz E
    Pharmacol Physicians; 1967 Jan; 1(1):1-6. PubMed ID: 6037148
    [No Abstract]   [Full Text] [Related]  

  • 49. Trends in antimicrobial consumption may be affected by units of measure.
    Dalton B; Sabuda D; Conly J
    Clin Infect Dis; 2007 Aug; 45(3):399-400; author reply 400-1. PubMed ID: 17599325
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: cockcroft-gault and modification of diet in renal disease.
    Golik MV; Lawrence KR
    Pharmacotherapy; 2008 Sep; 28(9):1125-32. PubMed ID: 18752383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
    Li C; Kuti JL; Nightingale CH; Nicolau DP
    J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of synergism in drug combinations and reference models for future orientations in oncology.
    Duarte D; Vale N
    Curr Res Pharmacol Drug Discov; 2022; 3():100110. PubMed ID: 35620200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toxicity interactions of cadmium, copper, and lead on soil urease and dehydrogenase activity in relation to chemical speciation.
    Chaperon S; Sauvé S
    Ecotoxicol Environ Saf; 2008 May; 70(1):1-9. PubMed ID: 18068781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Charting the Fragmented Landscape of Drug Synergy.
    Meyer CT; Wooten DJ; Lopez CF; Quaranta V
    Trends Pharmacol Sci; 2020 Apr; 41(4):266-280. PubMed ID: 32113653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mode of action as a determining factor in additivity models for chemical mixture risk assessment.
    Lambert JC; Lipscomb JC
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):183-94. PubMed ID: 17804132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose.
    Bergman KL
    Clin Pharmacol Ther; 2009 Sep; 86(3):328-31. PubMed ID: 19571806
    [No Abstract]   [Full Text] [Related]  

  • 57. Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.
    Zhao L; Au JL; Wientjes MG
    Curr Cancer Drug Targets; 2017; 17(8):735-755. PubMed ID: 28359247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimicrobial dosing considerations in obese adult patients.
    Pai MP; Bearden DT
    Pharmacotherapy; 2007 Aug; 27(8):1081-91. PubMed ID: 17655508
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What is synergy? The Saariselkä agreement revisited.
    Tang J; Wennerberg K; Aittokallio T
    Front Pharmacol; 2015; 6():181. PubMed ID: 26388771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.